Agnoprotein of mammalian polyomaviruses  by Gerits, Nancy & Moens, Ugo
Virology 432 (2012) 316–326Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroAgnoprotein of mammalian polyomavirusesNancy Gerits, Ugo Moens n
Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, NO-9037 Tromsø, Norwaya r t i c l e i n f o
Article history:
Received 13 February 2012
Returned to author for revisions
30 March 2012
Accepted 29 May 2012
Available online 21 June 2012
Keywords:
Agnoprotein
Interaction partner
Mutation
Post-translational modiﬁcation
Subcellular localization
Viroporin22/$ - see front matter & 2012 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2012.05.024
esponding author. Fax: þ47 77645350.
ail address: ugo.moens@uit.no (U. Moens).a b s t r a c t
Polyomaviruses are naked viruses with an icosahedral capsid that surrounds a circular double-stranded DNA
molecule of about 5000 base-pairs. Their genome encodes at least ﬁve proteins: large and small tumor
antigens and the capsid proteins VP1, VP2 and VP3. The tumor antigens are expressed during early stages of
the viral life cycle and are implicated in the regulation of viral transcription and DNA replication, while the
capsid proteins are produced later during infection. Members of the Polyomaviridae family have been
isolated in birds (Avipolyomavirus) and mammals (Orthopolyomavirus and Wukipolyomavirus). Some
mammalian polyomaviruses encode an additional protein, referred to as agnoprotein, which is a relatively
small polypeptide that exerts multiple functions. This review discusses the structure, post-translational
modiﬁcations, and functions of agnoprotein, and speculates why not all polyomaviruses express this protein.
& 2012 Elsevier Inc. All rights reserved.Introduction
Discovery of polyomaviruses
In 1953, Ludwig Gross accidently discovered the ﬁrst polyoma-
virus as a contaminant of murine leukemia virus. He observed that
mice inoculated with murine leukemia virus not only developed
leukemia, but also adenocarcinomas of the parotid gland (Gross,
1953). Newborn mice injected with extracts of parotid gland cancer
tissue developed a variety of solid tumors. Because of this property,
the new infectious agent was originally named murine SE poly-
omavirus after the Greek for many (poly) for and cancer (oma)
(Stewart et al., 1957).
In the following years several other polyomaviruses were
isolated from birds and mammalians, including man (Table 1).
So far, no polyomavirus infections have been recognized in ﬁsh,
amphibians or reptiles, although polyomaviruses-like particles
have been observed in these species, and the genome of a virus
infecting the Japanese eel contains one open reading frame that
shows homology to polyomavirus LT-ag (Essbauer and Ahne,
2001; Mizutani et al., 2011). Eight genuine human polyoma-
viruses (HPyV) have been described so far: BKPyV, JCPyV, KIPyV,
WUPyV, Merkel cell polyomavirus (MCPyV), HPyV6, HPyV7,
trichodysplasia spinulosa-associated polyomavirus (TSPyV), and
HPyV9 (Allander et al., 2007; Gardner et al., 1971; Gaynor et al.,
2007; Padgett et al., 1971; Feng et al., 2008; Schowalter et al.,
2010; Scuda et al., 2011; van der Meijden et al., 2010). HPyVs
seem to be harmless in immunocompetent individuals, but havell rights reserved.been associated with nephropathy (BKPyV), PML (JCPyV), and
trichodysplasia spinulosa (TSPyV) in immunocompromised patients
and with Merkel cell carcinoma (MCPyV) (Brew et al., 2010; Hirsch
and Steiger, 2003; Feng et al., 2008; van der Meijden et al., 2010).
The polyomavirus particle
In the sixties, the monkey polyomavirus simian virus 40
(SV40) was isolated and became the ﬁrst polyomavirus whose
complete genome was sequenced (Fiers et al., 1978). Sequence
analyses of other polyomavirus genomes conﬁrmed that they all
have a similar functional organization encoding the large (LT-ag)
and small tumor antigen (st-ag) proteins and the capsid proteins
VP1, VP2 and VP3. The virions lack an envelope, but contain an
icosahedral capsid of approximately 40–45 nm in diameter that
encloses a single copy of a 5000 base-pair double stranded,
circular DNA molecule (Imperiale and Major, 2007).
The viral genome is packed with cellular histones H2A, H2B, H3
and H4, except for the non-coding region, which contains the origin of
replication and controls expression of the viral genes (Imperiale and
Major, 2007). The early transcripts for LT- and st-ag are derived by
alternative splicing of a common precursor. The resulting LT- and st-
ag proteins are involved in viral DNA replication and transcription
(Gjoerup and Chang, 2010; Moens et al., 2007). Two major late
transcripts encode the capsid proteins; one of the transcripts is
translated into VP1, while the other gives rise to VP2 and VP3 by
using two different start codons (Imperiale and Major, 2007).
Agnoprotein
Although all polyomavirus genomes contain open reading
frames for the above-mentioned ﬁve proteins, several members
Table 1
Polyomaviruses whose genomes have been completely sequenced.
Polyomaviruses Agnoprotein aaa Accession number References
Mammalia
Primates
Human
BKV (WW strain) þ 62 NC_001538 (Seif et al., 1979)
JCV (Mad1 strain) þ 71 NC_001699 (Frisque et al., 1984)
KI (isolate Stockholm 60)  NC_009238 (Allander et al., 2007)
WU (strain B0)  NC_009539 (Gaynor et al., 2007)
MCPyV (isolate MCC350)  NC_010277 (Feng et al., 2008)
HPyV-6 (isolate 607a)  NC_014406 (Schowalter et al., 2010)
HPyV-7 (isolate 713a)  NC_014407 (Schowalter et al., 2010)
Trichodysplasia spinulosa-associated polyomavirus  NC_014361 (van der Meijden et al., 2010)
HPyV-9  NC_015150 (Scuda et al., 2011)
Monkey
SV40 þ 66 NC_001669 (Fiers et al., 1978)
SV40-Ri257 þ 90 FN812745 (Fagrouch et al., 2011)
Baboon polyomavirus 1 (isolate SA12) þ 68 NC_007611 (Cantalupo et al., 2005)
Chimpanzee polyomavirus þ 64/65/74 FR692334-6 (Deuzing et al., 2010)
Gorilla gorilla gorilla polyomavirus  HQ385752 (Leendertz et al., 2011)
Squirrel monkey polyomavirus þ 70 NC_009951 (Verschoor et al., 2008)
Lymphotropic polyomavirusb  NC_004763 (Pawlita et al., 1985(
Orangutan polyomavirus (Borneo isolate)  NC_013439 (Groenewoud et al., 2010)
Orangutan polyomavirus (Sumatra isolate)  FN356901 (Groenewoud et al., 2010)
Carnivora
California sea lion polyomavirus (strain CSL6994) þ 50 NC_013796 (Colegrove et al., 2010)
Artiodactyla
Bovine polyomavirus þ 118 NC_001442 (Schuurman et al., 1990)
Rodentio
Murine polyomavirus  NC_001515 (De Simone et al., 1985)
Murine pneumotropic virus (strain Kilham)  NC_001505 (Mayer and Dorries, 1991)
Hamster polyomavirus  NC_001663 (Delmas et al., 1992)
Mastomys polyomavirus þ 154 AB588640 (Orba et al., 2011)
Chiroptera
Myotis polyomavirus (little brown bat; isolate 14) þ 30 NC_011310 (Misra et al., 2009)
Aves
Canary polyomavirus  GU345044 (Halami et al., 2010)
Budgerigar ﬂedging or avian polyomavirus  NC_004764 (Rott et al., 1998)
Finch polyomavirus  NC_007923 (Johne et al., 2006)
Crow polyomavirus  NC_007922 (Johne et al., 2006)
Goose hemorrhagic polyomavirus  NC_004800 (Johne and Mu¨ller, 2001)
a Number of amino acid residues.
b African green monkey polyomavirus.
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Frisque 1995; Zerrahn et al., 1993). One of these polypeptides was
ﬁrst identiﬁed in the SV40 genome and is encoded by an open
reading frame upstream of the genes for the capsid proteins.
Because the existence of this gene product could not be demon-
strated at ﬁrst, this gene was referred to as agnogene and its
putative 66 amino acids protein as agnoprotein (derived from the
Greek ‘‘agnosis’’ meaning without knowledge) (Jay et al., 1981).
Later studies conﬁrmed the existence of the SV40 agnoprotein and
expression of agnoprotein or the presence of a putative agnogene
has been described for several other polyomaviruses (Table 1). This
review will elaborate on the structure and function of agnoprotein
and will discuss the importance of this protein for polyomaviruses.Biochemical properties of the polyomavirus agnoprotein
Primary structure
The genomes of the ﬁrst identiﬁed human polyomaviruses BK
and JC (BKV or BKPyV and JCV or JCPyV according to the
recommendations of the International Committee on Taxonomy
of Viruses; (Johne et al., 2011)) contain the agnogene and expressthis protein in infected cells (Rinaldo et al., 1998; Okada et al.,
2001; Safak et al., 2001). BKPyV and JCPyV agnoproteins display
high similarities with the SV40 agnoprotein, especially in the
N-terminal region (Fig. 1). In contrast, none of the recently
detected human polyomaviruses KI, WU, MCPyV, HPyV 6, HPyV7,
TSPyV, and HPyV9 seem to encode agnoprotein (Allander et al.,
2007; Feng et al., 2008; Gaynor et al., 2007; Schowalter et al.,
2010; Scuda et al., 2011; van der Meijden et al., 2010). Some other
mammalian polyomaviruses encode agnoprotein (Table 1). The
late region of Avipolyomavirus genomes encode a fourth protein
that was originally designated as agnoprotein (Johne and Mu¨ller,
2001). However, this structural protein is present in the virion
and has no functional homology to the agnoprotein of mamma-
lian polyomaviruses and is therefore currently referred to as VP4
(Johne and Mu¨ller, 2001).
Two striking features of agnoprotein from the different polyoma-
viruses are the high variability in length, and their sequence
homology (Fig. 1). The length of agnoprotein ranges from 30 amino
acids in bat polyomavirus to 118 residues in bovine polyomavirus,
while amino acid sequence identity diverges from no to almost 90%
identity (Table 2). Interestingly, the agnoproteins of BKPyV and JCPyV
are 450% identical to agnoprotein of the monkey polyomaviruses
SV40 and SA12. The close resemblance between the agnoproteins of
Fig. 1. Alignment of the amino acid sequences of the agnoprotein from different polyomaviruses. The single letter amino acid code is used. Red represents small and
hydrophobic amino acids (A, F, I, L, M, P, V, W), blue symbolizes acidic amino acids (D, E), magenta corresponds to basic amino acids (K, R), and green stands for hydroxyl,
amine and basic amino acids (C, G, H, N, Q, S, T, Y). An asterisk indicates an identical amino acid. The domain required for oligomerization is shaded in yellow. Putative
ubiquitination sites are underlined (Tung and Ho, 2008; Lee et al., 2011). The Clustal series of programs were used for multiple alignments (Chenna et al., 2003).
Table 2
Amino acid identity (in %) between agnoprotein of different polyomaviruses. The EMBOSS needle pairwise sequence alignment algorithm was used.
Agno BKPyV JCPyV SV40 Ri257 SA12 ChPyV1 ChPyV2 ChPyV3 SqPyV SLPyV BPyV MaPyV MyPyV
BKPyV 100 60 59.1 37.8 68.4 3.9 6.7 7.2 12.4 4.9 12.4 11.9 12.1
JCPyV 100 52.1 38.2 66.2 9.3 5.5 6.7 8.7 4.6 14.7 8.1 4.7
SV40 100 57.1 63.2 10.0 9.7 12.7 12.5 5.1 12.3 9.3 12.9
Ri257 100 44.1 12.4 6.6 9.3 18.2 3.9 16.3 2.8 13.2
SA12 100 10.1 7.5 10.1 15.7 4.8 13.3 12.3 11.1
ChPyV1 100 75.0 71.1 10.4 1.7 4.4 5.3 5.2
ChPyV2 100 89.2 12.0 1.9 4.4 10.3 13.8
ChPyV3 100 12.1 14.3 5.0 3.2 14.1
SqPyV 100 12.3 2.2 4.7 11.8
SLPyV 100 0 1.0 13.3
BPyV 100 18.3 1.4
MaPyV 100 1.8
MyPyV 100
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from divergence from a common ancestor.
Aside from squirrel, bovine and mastomys PyV which have
several methionines, all other agnoproteins contain just one methio-
nine that functions as the start codon. Other sequence peculiarities
comprise a statistical overrepresentation of the basic amino acids Arg
and Lys, the hydrophobic residues Leu and Val and the phosphoac-
ceptor sites Ser and Thr. On the other hand, His residues are mostlyabsent, as is the phosphoacceptor residue Tyr. The biological
implications of these amino acid compositions are not clear (Fig. S1).
Several substitutions in agnoprotein of BKPyV and JCPyV have
been identiﬁed in clinical isolates, while few or no data are
available for the other PyV (Table S1). Most changes are single
amino acid substitutions, but some isolates display deletions and
insertions. The majority of the mutations seem to concentrate in
the central and C-terminal regions (Table S1). It remains to be
N. Gerits, U. Moens / Virology 432 (2012) 316–326 319examined whether these mutations affect the structural and
functional properties of agnoprotein.
Post-translational modiﬁcation sites and functional implications
Phosphorylation and stability
The agnoproteins of BKPyV (Rinaldo et al., 1998; Johannessen
et al., 2008), JCPyV (Okada et al., 2001; Sariyer et al., 2006) and
SV40 (Jackson and Chalkley, 1981) are phosphoproteins. For BKV
and JCV, phosphoacceptor sites have been mapped to Ser-7,
Ser-11, and Thr-21 (Johannessen et al., 2008; Sariyer et al.,
2006). Ser-7 and Ser-11 are also conserved in SV40, SV40 Ri257
and SA12 agnoprotein, while Thr-21 is conserved in SA12 agno-
protein, and replaced by Ser-21 in SV40 agnoprotein. BKPyV,
JCPyV, SV40, SV40 Ri257 and SA12 contain a conserved Ser or Thr
at position 45 (44 in SV40 Ri257), but the in vivo functionality of
this phosphoacceptor site is not known. Agnoproteins encoded by
other non-human polyomaviruses also contain putative phos-
phoacceptor sites, e.g., agnoproteins of the chimpanzee polyoma-
virus strains Ta, Az and Bob comprise conserved Thr-3, Ser-15,
Ser-20, Thr-26, Ser-32, Thr-44, Thr-46/48, and Ser-53/55
(Table 3). It remains to be conﬁrmed whether these represent
genuine phosphoacceptor sites and the possible biological implica-
tions of phosphorylation of these sites are unknown. Tyrosine,
another phoshoacceptor site, is absent (ChPyV-Az, BKPyV, SV40,
SA12, SqPyV) or rare (1 residue in ChPyV-Ta, ChPyV-Bob, JCPyV,
SV40 Ri257, SLPyV, MyPyV and 4 in MaPyV) in the agnoproteins of
all known polyomaviruses (Fig. 1). The reason for this is unknown.
Single and double replacement of Thr-21 and Ser-7 plus Ser-11
with Ala in JCPyV agnoprotein generated mutant viruses that
failed to propagate (Sariyer et al., 2006). Replacing Ser-11 with
either non-phosphorylatable alanine or phospho-mimicking
aspartic acid in BKPyV agnoprotein reduced the ability of these
mutants to propagate compared to wild-type virus (Johannessen
et al., 2008). JCPyV DNA encoding an agnoprotein in which Ser-7
was replaced with Leu or Ser-11 with Phe has been ampliﬁed
from single patients in Russia and Ethiopia, respectively (GenBank
accession numbers BAB93095.1 and BAE02911.1, respectively).
A BKPyV isolate with deletion of residues 9–12 (removing Ser-11)
has also been reported (Chen et al., 2004). These ﬁndings may
indicate that virus genomes carrying mutations affecting these
phosphoacceptor sites can still sustain viral replication. However,
since the agnogene sequences were ampliﬁed by PCR, it is notTable 3
Biochemical properties of polyomavirus agnoprotein.
BKPyV JCPyV SV40 SV40Ri257
aa 66 71 61 118
kD 7.4 8.1 7.3 10.3
pI 10.0 10.1 10.1 9.7
DNA binding ss, ds
Phosphorylation S7,11,52,62,66
T21
S7,11,15,55
T21 Y62
S7,11,17,21
T19,45,57,62
S7,11,17, 62
T19,21,45,56
Acetylation K60,64 K9,13,69 K13,59 K13
Methylation K22,R41 K9,22 K51
ubiquitination K13,22,64 K9,13,69 K13,49,59
Glycosylation S7,53,62,6 S7,11,15, S7,17,62
6 T61,71 T62
Glycation 22 9,22,23,49 22,52
Subcellular
localization
C, PN 4Na C, PN 4N C, PN 4N NTb
NES 31–37 30–37 33–37 33–37
The ExPASy bioinformatics program was used to calculate the theoretical pI and mole
a C¼cytoplasmic, PN¼perinuclear, N¼nuclear; 4 means more prominent.
b NT¼not tested.known whether actual infectious virus particles were present in
the human samples or whether viral DNA was released from dead
cells. Alternatively, several viral strains may circulate in the same
patient and strains that express wild-type agnoprotein can rescue
strains expressing the phosphoagnoprotein mutants. Indeed, it
has been shown that agnoprotein in trans can rescue propagation
of SV40 and BKPyV strains that do not express agnoproteins in
cell culture (Carswell et al., 1986; Myhre et al., 2010).
Studies with non-phosphorylatable agnoprotein mutants
demonstrated that phosphorylation affects the stability of agno-
protein. Expression levels of single T21A, double S7A/S11A, and
triple S7A/S11A/T21A mutant proteins were higher than those of
wild-type JCPyV agnoprotein, whereas BKPyV S11A agnoprotein
was less stable than wild-type or the phosphomimicking S11D
mutant protein (Johannessen et al., 2008; Sariyer et al., 2006).
Results from both studies suggest that agnoprotein degradation is
modulated by residue-speciﬁc phosphorylation. Sariyer et al. did
not examine the stability of JCPyV S11A agnoprotein, but phos-
phorylation of Ser-11 may increase the stability of agnoprotein,
while phosphorylation of Ser-7 and Thr-21 may trigger degradation.
Phosphorylation of a substrate can stimulate its ubiquitination and
subsequent degradation by the proteasome (Hunter, 2007). It is not
known whether phosphorylation of agnoprotein leads to its ubi-
quitination and subsequent degradation, but in silico prediction
algorithms of ubiquitin-conjugated sites show that agnoproteins of
different polyomaviruses contain putative lysine ubiquitin acceptor
residues (Table 3, (Lee et al., 2011; Tung and Ho, 2008)).
Phosphorylation may also inﬂuence the subcellular location of
agnoprotein (see ‘‘Subcellular localization of agnoprotein’’ section).
Other post-translational modiﬁcations
Apart from phosphorylation, no other post-translational mod-
iﬁcations have been demonstrated to occur for agnoprotein.
Putative sumoylation, acetylation and methylation sites are pre-
sent in agnoprotein (Table 3, (Kiemer et al., 2005; Li et al., 2006;
Ren et al., 2009; Shao et al., 2009)), but whether these modiﬁca-
tions occur in vivo remains to be proven.
Secondary structure
The central part of BKPyV, JCPyV, SV40 and SA12 agnoprotein
contains a stretch of hydrophobic residues and is predicted to
form an a-helix (Fig. S2). The crystal structure of agnoprotein hasSA12 ChPyV-
Az
ChPyV-
Ta
ChPyV-
Bob
SqPyV BPyV SLPyV MyPV MaPyV
68 64 65 76 70 114 50 30 154
7.8 7.3 7.5 8.8 7.8 13.2 5.3 3.7 17.6
9.8 11.2 10.9 11.6 10.4 4.6 10.1 12.0 7.6
K52,65,66 K65 K62 K4 K2,3,50 K105
K50,51 K8,60 K8,62 K30
NTb NTb NTb NTb NTb NTb NTb NTb NTb
25–36 25–
36
cular mass values (Bjellqvist et al., 1994).
N. Gerits, U. Moens / Virology 432 (2012) 316–326320not been solved, but a computer-generated structural model of
JCPyV agnoprotein predicts that the N-terminal and central
regions (residues 17–43) of agnoproteins adopt an a-helical
structure (Saribas et al., in press). The SV40 Ri257 variant has a
hydrophobic region in the N-terminal part of its agnoprotein (this
part is conserved in SV40), while the unique C-terminal region
contains an additional hydrophobic region (Fig. S2). Agnoproteins
of other PyV lack a pronounced hydrophobic region. Circular
dichroism studies using full-length BKPyV agnoprotein have
conﬁrmed that the central part of agnoprotein adopts a helical
structure (N.G., unpublished results).
JCPyV, BKPyV and SV40 agnoproteins form stable dimers and
oligomers (Suzuki et al., 2010; Saribas et al., in press). Saribas and
colleagues demonstrated that the amino acids spanning from 17
to 42 are absolutely required for JCPyV agnoprotein oligmeriza-
tion (Saribas et al., in press). This region is extremely well-
conserved in BKPyV, SV40, SA12 agnoprotein, suggesting that this
domain may also be involved in oligomerization of these proteins.
Interestingly, viral particles were efﬁciently released from SVG-A
cells transfected with JCPyV DNA lacking the nucleotides
encoding amino acids 17–42 of agnoprotein, but were mostly
deﬁcient in DNA content (Saribas et al., in press). SV40 mutants
with deletions in agnoprotein removing this oligomerization
domain replicated less efﬁciently than wild-type virus (Barkan
and Mertz, 1981). These results suggest that agnoprotein
dimerization/oligomerization is implicated in viral encapsida-
tion of JCPyV DNA. The exact residues necessary for oligomer-
ization have not been mapped, but JCPyV, BKPyV and SV40
strains with speciﬁc amino acid substitutions in the 17–42
region have been isolated (see Table S1), indicating that these
residues may not be involved in agnoprotein oligomerization.
It is, however, likely that several amino acids are required such
that one single substitution will not abrogate agnoprotein
oligomerization.Subcellular localization of agnoprotein
Amino acid motifs that may control nucleo-cytoplasmic localization
of agnoprotein
The small size of agnoproteins (varying between 30–154 resi-
dues with estimated molecular mass ranging from 3.7 to 17.6 kD)
predicts that agnoprotein can shuttle between the cytoplasm and
the nucleus (Mattaj and Englmeier, 1998). Experimental studies
demonstrated that agnoprotein resides mainly in the cytoplasm
and perinuclear region, although a minor fraction is also detectable
in the nucleus (Carswell et al., 1986; Endo et al., 2003; Johannessen
et al., 2008; Myhre et al., 2010; Nomura et al., 1983; Okada et al.,
2001). The agnoproteins of BKPyV, JCPyV, SV40, and SA12 contain a
putative Leu-rich nuclear export signal (NES) in the central region
of the protein and a stretch of basic amino acids (R or K) which may
represent a classic nuclear localization signal (NLS) (Fig. 1, (Fu et al.,
2011; Lange et al., 2007)). Chimpanzee agnoprotein possesses a
bipartite motif (RRRRX5RX4RK) with two stretches of basic amino
acids, while the N-terminal regions of MyPyV, squirrel PyV and sea
lion PyV agnoproteins are R/K-rich. A putative NES motif is lacking
in agnoproteins of the latter. Studies with agnoprotein mutants in
the NES are required to conﬁrm the functionality of this motif.
Phosphorylation may regulate subcellular localization of a pro-
tein through conformational changes that expose a NES or NLS, or
through provoking the binding to or the release from an interacting
partner (Whitmarsh and Davis, 2000). One report indicates that the
subcellular distribution of agnoprotein may be regulated in a
phosphorylation-dependent manner. Okada and colleagues foundthat treatment of cells with H89, a cAMP-dependent protein kinase/
protein kinase A (PKA) and mitogen-activated protein kinase MSK1
inhibitor (Davies et al., 2000), retained JCPyV agnoprotein in the
nucleus (Okada et al., 2001). It is not known whether agnoprotein is
a bona ﬁde PKA/MSK1 substrate, and if so, which residues are
phosphoacceptor sites that may be involved in regulating the
subcellular residence of agnoprotein.
Cytoplasmic anchorage
Cytoplasmic anchorage to the cytoskeleton may also explain
the subcellular distribution of agnoprotein because JCPyV agno-
protein colocalizes with tubulin (Endo et al., 2003). A recent study
showed that JCPyV agnoprotein also localizes to the plasma
membrane and in the endoplasmatic reticulum (Suzuki et al.,
2010). Its association with the plasma membrane probably relates
to agnoprotein acting as a viroporin.
Lipid droplets
The Hirsch group showed that BKPyV agnoprotein can be
detected in lipid droplets and that this co-localization requires
residues 20–42 (Unterstab et al., 2010). Lipid droplets are phos-
pholipid monolayers derived from inside the lipid bilayer of the ER.
On the monolayers of such droplets, proteins (e.g., caveolin-1)
accumulate which lend structure and attribute a particular func-
tion to the droplet (Brown, 2001). The agnoproteins of BKPyV, SV40
and SA12 all contain a degenerated caveolin-1 consensus motif
FXXXXFXXF or FXFXXXXF (where F represents W, F and Y)
FXFXXXXXXXF, while JCPyV agnoprotein contains the motif
LXFXXXFXXXF (Fig. 1). Binding of these agnoproteins to caveolin
has not been reported, but the motif overlaps with the region
required for co-localization of BKPyV agnoprotein with lipid droplets
(Unterstab et al., 2010). a-soluble N-ethylmaleimide-sensitive fusion
attachment protein (a-SNAP), another interaction partner of BKPyV
agnoprotein, is found in lipids and may explain the presence of
agnoprotein in lipid droplets (Johannessen et al., 2011).Agnoprotein interaction partners
The agnoproteins of BKPyV and JCPyV have been shown to
interact with other viral and cellular proteins (Table 4). Interac-
tion partners for agnoprotein from other PyV have not yet been
identiﬁed and the low sequence identity between agnoproteins of
different PyV suggests that similar interactions as those found for
JCPyV and BKPyV agnoproteins are unlikely.
LT-ag, st-ag and PP2A
JCVPyV agnoprotein can interact with LT-ag, st-ag and PP2A
(Table 4). The physical interaction of JCPyV agnoprotein with LT-
ag downregulates both LT-ag mediated viral gene expression and
DNA replication (Safak et al., 2001). At the late stage of viral
infection, expression and replication of the viral genome has to
cease in order to prevent disproportionate production of genome
copies and capsid proteins and to optimize efﬁcient assembly
(Safak et al., 2001). JCPyV agnoprotein was shown to interact
directly with PP2A, which required agnoprotein residues 18–36
(Sariyer et al., 2008). PP2A dephosphorylated PKC-phosphorylated
agnoprotein. The authors demonstrated that JCPyV agnoprotein
also binds st-ag, but the agnoprotein domain necessary for
interaction with st-ag was not mapped, implying that is not
known whether PP2A and st-ag can bind their common substrate
simultaneously or in a mutually exclusive manner. However,
Table 4
Identiﬁed interaction partners for agnoprotein.
PyV Interaction partner Functional implication Interacting domain
partner
Interacting domain
agnoprotein
Reference
BKPyV a-SNAP Interference secretion Not determined N-terminus (Johannessen et al., 2011)
PCNA Inhibition DNA synthesis our unpublished results
p50a Unknown Unknown Unknown (Rinaldo et al., 1998)
p75 Unknown Unknown Unknown (Rinaldo et al., 1998)
p100 Unknown Unknown Unknown (Rinaldo et al., 1998)
JCPyV FEZ1 Facilitates viral release Coiled-coil domain Not determined (Suzuki et al., 2005)
HP1a Nuclear egress virions Not determined N-terminus (Okada et al., 2005)
Ku70 Aberrant DNA repair Not determined N-terminus (Darbinyan et al., 2004)
Tumor suppressor
p53
Dysregulation cell cycle Not determined N-terminus (aa 1–36) (Darbinyan et al., 2002)
p52a Unknown Unknown Unknown (Endo et al., 2003)
p103 Unknown Unknown Unknown (Endo et al., 2003)
p112 Unknown Unknown Unknown (Endo et al., 2003)
p158 Unknown Unknown Unknown (Endo et al., 2003)
HIV-1 Tat Inhibition HIV-1 gene expression Residues 1–50 Residues 18–54 (Kaniowska et al., 2006)
Tubulin Unknown Unknown Unknown (Endo et al., 2003; Suzuki et al.,
2005)
YB-1 Altered gene expression C-terminal half Residues 18–36 (Safak et al., 2002)
LT-ag Repression viral transcription and DNA
replication
Central domain N-terminus (Safak et al., 2001)
st-ag Disrupt PP2A:st-ag interaction? C-terminus N-terminus (Sariyer et al., 2008)
PP2A Dephosphorylation of agnoprotein Not determined Residues 18–36 (Sariyer et al., 2008)
a JCPyV binds tubulin which has an estimated molecular mass of 54 kD. The p50 and p52 proteins known to interact with, respectively, BKPyV and JCPyV agnoprotein
may therefore represent tubulin.
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mediated inhibition PP2A, rather than st-ag preventing PP2A to
bind to agnoprotein. JCPyV deﬁcient in st-ag or encoding st-ag
lacking its unique C-terminal domain (and thus the PP2A binding
region) are replication incompetent (Sariyer et al., 2008; Bollag
et al., 2010). JCPyV genomes encoding agnoproteins in which the
PKC phosphoacceptor sites Ser-7, Ser-11, and Thr-21 were sub-
stituted by non-phosphorylatable Ala were also severely impaired
with respect to replication (Sariyer et al., 2006, 2008). siRNA-
mediated depletion of PP2A strongly reduced JCPyV replication in
SVG-A cells and reduced agnoprotein levels (Sariyer et al., 2008).
All these observations illustrate the biological importance of the
PP2A:st-ag:agnoprotein link for the viral life cycle.
The agnoprotein phosphorylation state was shown to mod-
ulate the function and stability of agnoprotein, and to affect
the propagation efﬁciency of the virus (Johannessen et al.,
2008; Sariyer et al., 2006). Depending on the relative concen-
tration of st-ag, PP2A, and agnoprotein, different complexes
can be envisaged during the viral life cycle. This will affect the
phosphorylation states of agnoprotein in a time-dependent
manner. During the early phase of infection, there will be an
excess of st-ag compared to agnoprotein and hence st-ag will
predominantly bind and inactivate PP2A. This will impede
PP2A-mediated dephosphorylation of agnoprotein. As the
viral life cycle of PyV progresses, more agnoprotein will be
synthesized, such that the likelihood to form agnoprotein:
st-ag complexes is increased. This will prevent st-ag from
binding and inactivating PP2A. As a result, PP2A may depho-
sphorylate agnoprotein. Strikingly, viral proteins of both RNA
and DNA viruses have been shown to physically interact with
PP2A and interfere with cell proliferation and survival. While
HIV-1 Vpr, Adenovirus E4orf, and hepatitis C virus NS5A
proteins induce cell cycle arrest and apoptosis by binding
PP2A (Georgopoulou et al., 2006; Li et al., 2009; Godet et al.,
2010), PP2A inactivation by Epstein-Barr virus EBNA-LP
protects against apoptosis (Garibal et al., 2007). HTLV-I Tax
and HPV E7 protein also binds and inactivates PP2A, but
the biological consequences for the viral life cycle remain
unknown (Pim et al., 2005; Hong et al., 2007).Heterochromatin protein 1a (HP1a)
Besides viral proteins, agnoprotein may also recruit cellular
proteins in its endeavor to optimize the host cell for viral
production. One of these is heterochromatin protein 1a (HP1a).
The nuclear envelope is composed of an inner and outer lipid
layer spiked with several proteins. The inner nuclear membrane
is connected to the nuclear lamina, which is composed of
lamins A, B1, B2 and C. The lamin B receptor is a part of the
inner nuclear membrane and binds HP1a. This interaction is
thought to contribute to the reassembly of the nuclear envelope
after cell division (Stewart et al., 2007). The N-terminal region
of JCPyV agnoprotein can associate with HP1a, resulting in
dissociation of HP1a from the lamin B receptor. This alters the
nuclear envelope and facilitates nuclear release of progeny
virus particles (Okada et al., 2005). Although the N-terminal
region is 90% identical with BKPyV agnoprotein, no co-localiza-
tion with HP1a in primary human renal tubule epithelial cells
was observed (Myhre et al., 2010; Unterstab et al., 2010). This
may indicate that the JCPyV agnoprotein amino acid residues
critical for the interaction with HP1a are not conserved in
BKPyV agnoprotein.Fasciculation and elongation protein zeta 1 (FEZ1)
JCPyV agnoprotein was shown to bind to FEZ1, a multifunctional
protein involved in neuronal differentiation, microtubule and
centrosomal organization, and transport of cargoes (Maturana
et al., 2010; Suzuki et al., 2005). This agnoprotein:FEZ1 association
induced the dissociation of FEZ1 from microtubules. The authors
speculated that FEZ1 prevents virion release and that agnoprotein
may prevent this inhibition, thereby promoting the intracellular
translocation of viral particles on microtubules (Suzuki et al., 2005).
Interestingly, JCPyV agnoprotein co-localizes with the cytoskeletal
protein tubulin, which oligomerizes to formmicrotubules. Although
the functional consequences are not understood, the interaction
between agnoprotein and tubulin could also support transport of
viral particles along microtubules (Endo et al., 2003).
N. Gerits, U. Moens / Virology 432 (2012) 316–326322Ku70
JCPyV agnoprotein binds directly to the DNA repair enzyme
Ku70, an event that inhibits DNA repair and disrupts DNA
damage-induced cell cycle arrest. Circumventing cell cycle arrest
associated with DNA repair may speed up the viral life cycle,
while impairment of DNA repair may contribute to cellular
transformation by JCPyV (Darbinyan et al., 2004).
p53
JCPyV agnoprotein was shown to bind p53 and this interaction
led to higher levels of p21Cip1/Waf-1 and accumulation of cells at
the G2/M phase. This stalling of the cells in G2/M phase may
allow efﬁcient virion assembly (Darbinyan et al., 2002). These
studies were, however, performed by ectopic overexpression of
agnoprotein in mouse ﬁbroblast NIH3T3 cells in the absence of
other JCPyV proteins and may therefore not reﬂect a bona ﬁde
infection in the natural host.
Y-box binding factor-1 (YB-1)
JCPyV agnoprotein binds the transcription factor YB-1 through
its N-terminal region (Safak et al., 2002). While association of
JCPyV LT-ag with YB-1 results in synergistic activation of the late
promoter, agnoprotein suppresses YB-1 mediated transcription of
the early and late viral promoter (Safak et al., 1999, 2002).
Hence, agnoprotein operates to shut off viral expression by target-
ing YB-1. The authors also demonstrated that YB-1, which is
predominantly found in the cytoplasm in uninfected SVG-A cells,
translocates to the nucleus during viral infection (Safak et al.,
2002). Interestingly, the nuclear YB-1 concentration increased as
viral life cycle proceeded, and decreased as the infection cycle
approached its termination (Safak et al., 2002). These data suggest
that agnoprotein may play a role in regulating the subcellular
localization of YB-1 since agnoprotein levels also ﬂuctuate during
the viral life cycle.Functions of agnoprotein
Regulation of gene expression
Changes in agnoprotein expression affect the expression of
other viral proteins. Deletions in SV40 agnogene, removal of the
complete JCPyV agnogene or mutation of its start codon (the
tetranucleotide CATG spanning the agnoprotein start codon was
converted into TCGA) all caused a drop in the levels of VP1 and
LT-ag (Barkan et al., 1987; Akan et al., 2006). Akan and co-workers
argued that the agnogene contains critical cis-acting DNA ele-
ments to which transcription factors bind and regulate viral gene
expression. Hence, deletion of the agnogene might remove these
binding sites and affect transcription of the LT-ag and VP1 genes.
However, as changing the tetranucleotide sequence CATG into
TCGA will not destroy as many putative transcription binding
sites as deleting the whole agnogene, it is possible that agnopro-
tein itself can affect the expression levels of LT-ag. How the lack of
agnoprotein inﬂuences the expression of LT-ag is not completely
understood, but it could be at the transcriptional level (e.g.,
agnoprotein interferes with the proteins involved in transcribing
the early genes) or at the post-transcriptional level (e.g., agno-
protein affects the stability of LT-ag). Another mechanism by
which agnogene DNA sequences can modulate the expression of
VP1 is at the post-transcriptional level by acting as an upstream
ORF (uORF). Several groups have shown that the synthesis of
some proteins can be modulated in part by translation of uORFencoded within the leader region of mRNA (Geballe and Sachs,
2000; Morris and Geballe, 2000). Similarly, the coding sequence
of agnoprotein may act as an uORF that controls the translation
rate of VP1 and hence the amount of VP1 synthesized in infected
cells. Indeed, Three groups independently observed higher intra-
cellular protein levels of VP1 in cells infected with SV40, JCPyV
or BKPyV mutants in which the translation initiation codon of
agnoprotein was destroyed than in cells challenged with wild-
type virus (Johannessen et al., 2008; Sedman et al., 1989; Suzuki
et al., 2010). This indicates that the agnoprotein ORF reduces the
translation of the downstream ORF VP1.
Viral DNA replication
LT-ag is indispensable for replication of the viral genome
(Imperiale and Major, 2007). As previously mentioned, the inter-
action of JCPyV agnoprotein with LT-ag down-regulates viral DNA
replication (Safak et al., 2001).
Viral maturation and release
Agnoprotein is expressed during later stages of viral infection
and it can therefore be assumed that it is involved in completing
the viral life cycle by stimulating viral maturation and/or viral
release. Although the exact function of agnoprotein remains
unresolved, several ﬁndings indicate that this protein is impli-
cated in viral maturation and release. First, cells infected with
SV40 agnoprotein deﬁcient mutants displayed an abnormal
nuclear localization of VP1. Agnoprotein was shown to facilitate
the perinuclear-nuclear localization of VP1 (Carswell and Alwine,
1986; Resnick and Shenk, 1986). Transfection of cells with mutant
SV40 or JCPyV genomes unable to express agnoprotein due to
mutation of their ATG codon results in the release of progeny
virions deﬁcient in DNA content (Resnick and Shenk, 1986;
Sariyer et al., 2006; Suzuki et al., 2010). Viral early and late
protein expression and viral DNA replication are reduced com-
pared to cells transfected with wild-type SV40 or JCPyV DNA.
Expression of agnoprotein in trans restored viral expression and
replication (Myhre et al., 2010; Sariyer et al., 2011). Vero cells
transfected with the genome of a mutant BKPyV strain Dunlop
that does not express agnoprotein can still produce infectious
virus particles, although less efﬁciently than wild-type virus
(Johannessen et al., 2008). On the other hand, Vero cells trans-
fected with recombinant BKPyV Dunlop genome in which the
non-coding region was replaced with non-coding regions of
isolates from renal transplant patients were unable to produce
infectious virions (Myhre et al., 2010). The NCCRs of these clinical
BKPyV isolates were rearranged and had large deletions in the
5’end of the agnogene. The recombinant viral genomes expressed
VP1, but not agnoprotein and after transfection, they produced
virus-like particles in the nucleus which were not released from
the cell. When released by artiﬁcial lysis of the cells these virus-like
particles turned out to be non-infectious (Myhre et al., 2010).
Deletion of JCPyV agnoprotein still resulted in efﬁcient release of
virus-like particles from SVG-A transfected cells (Sariyer et al.,
2011), while Suzuki and colleagues, using the same cells, observed
a strong decrease in the release of virus particles (Suzuki et al.,
2010). The reason why some groups ﬁnd that cells transfected
JCPyV and BKPyV genomes not encoding agnoprotein release virus
particles, while other investigators cannot, remains unclear.
Viruses such as poliovirus, rotavirus, HIV-1, HTLV-I, inﬂuenza-
virus, Coronavirus, Sindbis virus, SARS and Bluetongue all encode
proteins that promote release of progeny virions. These proteins,
referred to as viroporins, are small (60–120 amino acids) proteins
that possess at least one hydrophobic transmembrane domain able
to form an amphipatic a-helix (Gonzalez and Carrasco, 2003).
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that enhances viral release. Amino acids 8 (R) and 9 (K) were crucial
for viroporin activity (Suzuki et al., 2010). This N-terminal RK motif
is conserved in the agnoprotein of squirrel polyomavirus (residues
3 and 4 and residues 8 and 9) and of bovine polyomavirus (residues
11 and 12), but not in the closely related BKPyV, SV40 and SA12
(Fig. 1). Another group showed that SV40 VP4, a protein encoded by
an internal open reading frame in the VP2/VP3 coding sequence,
acts as a viroporin (Raghava et al., 2011). Both JCPyV and BKPyV
have a putative VP4 ORF, but the expression of this protein has not
been demonstrated. The other human polyomaviruses that do not
express an agnoprotein also lack this VP4 ORF (Van Ghelue et al., in
press). In addition to its viroporin function, the viroporins Vpu of
HIV-1 and M2 of inﬂuenza virus impair the secretory pathway
(Henkel et al., 2000; Tokarev and Guatelli, 2011). Similarly, BKPyV
agnoprotein also interferes with secretion through its interaction
with a-SNAP (Johannessen et al., 2011).Interference with secretion
Studies by our group have shown that agnoprotein binds to
a-SNAP, a protein involved in secretion (Johannessen et al., 2011).
Overexpression of agnoprotein inhibited secretion of the VSVG-
EFGP reporter, suggesting an inhibitory role of agnoprotein in
secretion. The biological importance is not yet understood, but
agnoprotein may interfere with membrane integrity, prevent
secretion of e.g., immunomodulators and viral antigens, or pre-
vent premature release of incomplete virus particles.Pathogenic potential of agnoprotein
JCPyV agnoprotein possesses oncogenic properties in cell culture
because it can interfere with apoptosis and cell cycle control
through targeting p53 and p21CIP-1/WAF-1, and perturb the activity
of Ku70, Ku80, p53 and FEZ1 which are involved the DNA repair
enzymes (Darbinyan et al., 2002, 2004, 2007; Suzuki et al., 2005).
Agnoprotein has also been detected in several cancers, including
colon cancer, primary CNS lymphoma, esophageal cancer and
medulloblastoma. Some cases of medulloblastoma had no detect-
able LT-ag expression, reinforcing the assumption that agnoprotein
may contribute to tumorigenesis (reviewed in Moens et al., 2007;
Del Valle and Khalili, 2010). However, a causal role of JCPyV in
cancer remains unclear (Maginnis and Atwood, 2009).
It was recently reported that agnoprotein plays a role in JCPyV-
induced dysregulation of chemokine production by oligodendro-
cytes (Merabova et al., 2011). Stable expression of agnoprotein in
the rat oligodendrocyte cell line CG4-OI compromised the release
of chemokine CXCL5/LIX, and to a lesser extent IL-10, TNF-a, and
Fractalkine. Neurons treated with conditioned medium from CG4-
OI cells displayed a higher survival rate than cells challenged with
medium from agnoprotein-expressing CG4-OI cells. Treatment of
neurons with conditioned medium from agnoprotein-expressing
CG4-OI cells induced apoptosis and was associated with activa-
tion of the p38MAPK and GSK3b pathways, while the ERK1/2
pathway was inhibited (Merabova et al., 2011). The mechanism
responsible for reduced CXCL5/LIX levels in medium of agnopro-
tein-expressing CG4-OI cells was not examined, but may result
from agnoprotein’s ability to interfere with transcription (Khalili
et al., 2005; Johannessen et al., 2008). JCPyV agnoprotein may also
compromise secretion of CXCL5/LIX through interference with
intracellular transport as was shown for BKPyV agnoprotein
through interaction with a-SNAP (Johannessen et al., 2011).Agnoprotein: Reason for existence?
It is unclear why not all polyomaviruses encode agnoprotein,
but the absence of agnoprotein in several members of the
Polyomaviridae may indicate that there is little evolutionary
selection pressure for the virus to possess this protein. This is
further supported by the high diversity of the agnoprotein amino
acid sequence between different polyomavirus strains (Table 2)
and the many mutations found (Table S1). In fact, it is the least
conserved protein in BKPyV strains. Analysis of 161 whole BKPyV
genomes showed that the amino acid variation rate was 11.9% for
agnoprotein, while it was 8.6% for VP2, 7.1% for VP2, and 4.2% for
LT-ag (Luo et al., 2008).Replication site
The presence of an agnogene in the PyV genome may depend
on the site of replication of the virus and the manner in which
virus particles are released. The dermotropic MCPyV, HPyV6,
HPyV7, and TSPyV do not encode agnoprotein. In accordance
with human papillomaviruses, they may infect cells in the basal
layer of cutaneous skin. For human papillomaviruses, hair follicles
may represent an important site of infection (Doorbar, 2005).
Interestingly, MCPyV, HPyV6, HPyV7, and TSPyV have been found
in hair follicles (reviewed in Moens et al., 2011). Mature papillo-
mavirus particles are not released until the infected cells reach
the upper skin layer (Doorbar, 2005). This may also be the case for
these human PyV and therefore these viruses do not depend on
the viroporin properties of agnoprotein.Fine-tuning the amount of virions released
Another function of agnoproten could be to ﬁne-tune the number
of virus particles produced and released. Shedding a limited number
of infectious virus particles may prevent the destruction of the
infected host cell and enable PyV to evade the immune system. This
may allow the virus to establish a persistent infection. The agno-
proteins of BKPyV, JCPyV and SV40 may function as uORFs that
reduce VP1 production, while virally encoded miRNA downregulates
LT-ag expression. Both mechanisms allow the virus to control the
number of progeny virions produced in an infected cell. The new
human polyomaviruses MCPyV, HPyV6 and HPyV7 all lack agno-
protein, but they seem to be continuously shed in high numbers
(e.g., 2106 MCPyV genome equivalents and 5103 HPyV6 gen-
ome equivalents) from the skin of healthy individuals (Schowalter
et al., 2010). However, intracellular retention of viral antigens occurs
until the infected cells reach the uppermost epithelial layers. Virions
released in this way may avoid encountering the immune system.
Therefore these viruses do not need agnoprotein to control the
amount and the way progeny virus particles are released.Co-infection dependency
Another possible explanation could be that non-agnoprotein
expressing HPyV depend on co-infection of agnoprotein-expres-
sing HPyV to complete their life cycle. Co-infection of humans by
several HPyV is not unlikely because seropositivity in the normal
population is 450% for each of the known HPyV and e.g., BKPyV
or JCPyV DNA have been detected in KIPyV and WUPyV positive
samples (Kean et al., 2009; Moens et al., 2010; Schowalter et al.,
2010; Trusch et al., 2012; van der Meijden et al., 2011). Supple-
mentation of agnoprotein in trans requires that the same cell is
simultaneously infected with a HPyV expressing agnoprotein and
a HPyV which lacks agnogene.
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The role of agnoprotein remains enigmatic in many ways, but
abrogation of agnoprotein expression impairs viral propagation
(Shenk et al., 1976; Myhre et al., 2010; Sariyer et al., 2011).
Despite its small size, agnoprotein seems to be a multifunctional
polypeptide implicated in viral transcription, replication, assem-
bly and maturation and release. Agnoprotein accomplishes these
tasks either by itself (viroporin), through interaction with other
viral proteins (LT-ag) or by associating with cellular proteins. The
functional implications of interactions with cellular partners are
not completely understood. The expression and function of
agnoprotein in PyV other than BKPyV, JCPyV and SV40 has not
been addressed. Studies aimed to elaborate the role of these
putative agnoproteins in the viral life cycle are necessary. Besides
their crucial role in viral replication, BKPyV and JCPyV agnopro-
teins have been detected in tumors. Moreover, cell culture studies
have shown that agnoprotein can affect cell cycle progression and
DNA repair (Del Valle and Khalili, 2010; Khalili et al., 2005). Thus,
agnoprotein may be an attractive target for viral therapy in
malignant and non-malignant (e.g., nephropathy, PML) diseases.
Antibodies raised against peptides encompassing the putative
agnoprotein of non-HPyV may help to determine whether agno-
gene in these viral genomes is expressed. The low degree of
similarity of these agnoproteins with BKPyV and JCPyV agnopro-
tein may indicate that they interact with non-related cellular
proteins and fulﬁll other functions. Finally, the identiﬁcation of
novel PyV in other species and humans may reveal new members
of the Polyomaviridae encoding agnoprotein and unveil the co-
evolution with their hosts.Acknowledgment
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